Zacks Research Comments on Encompass Health Co.'s Q2 2024 Earnings (NYSE:EHC)

Encompass Health Co. (NYSE:EHC - Free Report) - Investment analysts at Zacks Research lowered their Q2 2024 earnings estimates for Encompass Health in a research note issued on Wednesday, May 8th. Zacks Research analyst Z. Masood now anticipates that the company will post earnings per share of $0.98 for the quarter, down from their prior estimate of $0.99. The consensus estimate for Encompass Health's current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Encompass Health's Q4 2024 earnings at $0.99 EPS, FY2024 earnings at $4.03 EPS, Q4 2025 earnings at $1.16 EPS, FY2025 earnings at $4.45 EPS, Q1 2026 earnings at $1.27 EPS and FY2026 earnings at $5.20 EPS.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.93 by $0.19. The company had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.27 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The business's revenue for the quarter was up 13.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 EPS.

Several other analysts also recently commented on the stock. Truist Financial increased their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a "buy" rating in a report on Friday, February 9th. Royal Bank of Canada restated an "outperform" rating and issued a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Raymond James reaffirmed a "strong-buy" rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Stephens reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Encompass Health in a research note on Tuesday, January 16th. Finally, Barclays lifted their price target on shares of Encompass Health from $101.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $90.29.

Encompass Health Trading Up 0.2 %

Shares of NYSE:EHC traded up $0.16 during trading on Friday, reaching $86.53. The stock had a trading volume of 719,297 shares, compared to its average volume of 665,830. The firm's fifty day moving average is $80.00 and its 200 day moving average is $72.15. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. Encompass Health has a 52 week low of $57.55 and a 52 week high of $86.72. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of 23.39, a P/E/G ratio of 1.30 and a beta of 0.92.

Institutional Investors Weigh In On Encompass Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Principal Securities Inc. purchased a new position in shares of Encompass Health in the fourth quarter valued at $25,000. Benjamin F. Edwards & Company Inc. boosted its stake in Encompass Health by 360.2% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company's stock worth $27,000 after buying an additional 317 shares during the period. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Encompass Health in the fourth quarter valued at $30,000. GAMMA Investing LLC bought a new stake in shares of Encompass Health in the 4th quarter worth about $33,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Encompass Health during the 3rd quarter worth about $35,000. 97.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Encompass Health

In other news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total value of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Greg D. Carmichael bought 2,000 shares of Encompass Health stock in a transaction that occurred on Friday, May 3rd. The stock was bought at an average cost of $83.73 per share, with a total value of $167,460.00. Following the acquisition, the director now owns 17,050 shares of the company's stock, valued at approximately $1,427,596.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now directly owns 554,098 shares of the company's stock, valued at $46,139,740.46. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, June 28th. Encompass Health's dividend payout ratio (DPR) is presently 16.22%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.